| CAS NO: | 2186700-33-2 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
Ervogastat (PF-06865571) 是一种有效且耐受性良好的二酰基甘油酰基转移酶 2 抑制剂 (DGAT2i)。Ervogastat 单独使用可降低NASH 的脂肪变性和肝甘油三酯水平。Ervogastat 联合 Clesacostat (乙酰辅酶 a -羧化酶抑制剂 (ACCi)) 用于非酒精性脂肪性肝炎 (NASH) 伴肝纤维化治疗的研究。
| Cas No. | 2186700-33-2 |
| 别名 | (S)-2-(5-((3-乙氧基吡啶-2-基]氧基]吡啶-3-基)-N-(四氢呋喃-3-基)嘧啶-5-甲酰胺 |
| 分子式 | C21H21N5O4 |
| 分子量 | 407.42 |
| 溶解度 | DMSO : 125 mg/mL (306.81 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor (DGAT2i). Ervogastat alone reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH)[1]. Ervogastat combination with Clesacostat (an acetyl CoA-carboxylase inhibitor (ACCi)) can be used for the research of NASH with liver fibrosis therapy[1][2]. [1]. PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS |
m.cnreagent.com